International Archives of Health Sciences

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 8  |  Issue : 3  |  Page : 181--189

Differential expression of blaCTX-M-33 with vancomycin/trimethoprim combination in Escherichia coli-producing extended-spectrum β-lactamase isolated from intensive care unit-acquired urinary tract infection


Fatemeh Hosseini1, Alireza Khodavandi1, Fahimeh Alizadeh2 
1 Department of Biology, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran
2 Department of Microbiology, Yasooj Branch, Islamic Azad University, Yasooj, Iran

Correspondence Address:
Dr. Alireza Khodavandi
Department of Biology, Gachsaran Branch, Islamic Azad University, Gachsaran
Iran
Dr. Fahimeh Alizadeh
Department of Microbiology, Yasooj Branch, Islamic Azad University, Yasooj
Iran

Aim: The aim of this study was to develop combination approach for the treatment of Escherichia coli-producing extended-spectrum β-lactamases (ESBLs) isolated from intensive care unit (ICU)-acquired urinary tract infections (UTIs). Materials and Methods: The observational study was conducted between January 5, 2018- June 5, 2019 to isolate and detect E. coli from UTI patients admitted to ICUs in Shahid Rajaee hospital, Gachsaran, Iran. Morphological, biochemical and molecular methods were conducted to identify E. coli isolates. Phenotypic confirmation of E. coli producing ESBL was performed using ESBL disc diffusion test according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. The combination index assay set-up was based on CLSI guidelines to investigate antibacterial susceptibilities to vancomycin alone and in combination with trimethoprim and interpreted with the fractional inhibitory concentration (FIC) index. Eventually, the expression levels of blaCTX-M-33 gene were determined by real-time quantitative reverse transcription–polymerase chain reaction. Results: A total of 90 ICU-acquired UTIs occurred among 255 patients. The combination index assay results showed that vancomycin/trimethoprim combination would be reduced its minimal inhibitory concentration90 value. The vancomycin/trimethoprim combination revealed partial synergistic and indifferent effects (FIC = 0.52–1.50) in the isolates of E. coli-producing ESBL. The results of gene expression analysis indicated that vancomycin/trimethoprim combination caused downregulation of blaCTX-M-33 gene at negligible levels by 55.56–58.82-fold and stopped drug resistant. Conclusion: Vancomycin/trimethoprim combination may diminish resistance in the E. coli-producing ESBL isolated from ICU-acquired UTI patients.


How to cite this article:
Hosseini F, Khodavandi A, Alizadeh F. Differential expression of blaCTX-M-33 with vancomycin/trimethoprim combination in Escherichia coli-producing extended-spectrum β-lactamase isolated from intensive care unit-acquired urinary tract infection.Int Arch Health Sci 2021;8:181-189


How to cite this URL:
Hosseini F, Khodavandi A, Alizadeh F. Differential expression of blaCTX-M-33 with vancomycin/trimethoprim combination in Escherichia coli-producing extended-spectrum β-lactamase isolated from intensive care unit-acquired urinary tract infection. Int Arch Health Sci [serial online] 2021 [cited 2022 Dec 1 ];8:181-189
Available from: http://www.iahs.kaums.ac.ir/article.asp?issn=2383-2568;year=2021;volume=8;issue=3;spage=181;epage=189;aulast=Hosseini;type=0